Wamlox 5 mg/80 mg filmom obalené tablety Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

wamlox 5 mg/80 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - valsartan a amlodipín - 58 - hypotensiva

Valzap HCT 160 mg/12,5 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

valzap hct 160 mg/12,5 mg

zentiva, k.s., Česká republika - valsartan a diuretiká - 58 - hypotensiva

Valzap HCT 160 mg/25 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

valzap hct 160 mg/25 mg

zentiva, k.s., Česká republika - valsartan a diuretiká - 58 - hypotensiva

Vasopentol HCT 80/12,5 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vasopentol hct 80/12,5 mg

egis pharmaceuticals plc, maďarsko - valsartan a diuretiká - 58 - hypotensiva

Vasopentol HCT 160/12,5 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vasopentol hct 160/12,5 mg

egis pharmaceuticals plc, maďarsko - valsartan a diuretiká - 58 - hypotensiva

Vasopentol HCT 160/25 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vasopentol hct 160/25 mg

egis pharmaceuticals plc, maďarsko - valsartan a diuretiká - 58 - hypotensiva

Entresto Den europeiske union - slovakisk - EMA (European Medicines Agency)

entresto

novartis europharm limited - sacubitril, valsartan - zástava srdca - angiotensin ii protivníci, ďalšie kombinácie, agentov konajúcich na renin-angiotensin system - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Neparvis Den europeiske union - slovakisk - EMA (European Medicines Agency)

neparvis

novartis europharm limited - sacubitril, valsartan - zástava srdca - Činidlá pôsobiace na systém renín-angiotenzín - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.